Table 2 Characteristics of included studies
study | country | HCC/controls | tumor staging (TNM) | GP 73 | AFP | ||
|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | assay type | cutoff value | assay type | cutoff value |
Hu2009 | China | 31/93 | NKb | westernblot | 7.4 RUa | ELISA | 36 ug/L |
Morota2011 | USA | 70/156 | NK | ELISA | 94.7 ug/L | ELISA | 15.3 ug/L |
Ozkan2010 | Turkey | 75/83 | 3/20/14/38 | ELISA | 2.36 ug/L | ELISA | 4.36 ug/L |
Mao2010 | China, USA | 789/3428 | NK | immunoblot | 8.5 RU | ELISA | 35 ug/L |
Marrero2005 | USA | 144/108 | 17/52/59/16 | immunoblot | 10 RU | ELISA | 99 ug/L |
Tian2010 | China | 153/219 | 23/95/30/5 | ELISA | 113.8 ug/L | ELISA | 13.6 ug/L |
Wang2009 | USA | 164/113 | 38/70/34/22 | immunoblot | NK | ELISA | NK |
Shi2011 | China | 55/107 | NK | ELISA | 100 ug/L | ELISA | 400 ug/L |